NDAORALCAPSULEPriority Review
Approved
Nov 1960
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
Priority Review
ZARONTIN (ethosuximide) by Pfizer is clinical pharmacology ethosuximide suppresses the paroxysmal three cycle per second spike and wave activity associated with lapses of consciousness which is common in absence (petit mal) seizures. Approved for epilepsy. First approved in 1960.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZARONTIN (ethosuximide) is an oral anti-epileptic agent approved in 1960 that suppresses the characteristic 3 Hz spike-and-wave activity associated with absence seizures by depressing the motor cortex and elevating seizure threshold. It is indicated for the treatment of absence (petit mal) epilepsy and remains a foundational therapy for this specific seizure type.
$0.217MPart D
LOE ApproachingStable
This aging, low-volume product faces imminent loss of exclusivity and carries minimal commercial opportunity; brand team is likely small and focused on retention.
Mechanism of Action
CLINICAL PHARMACOLOGY Ethosuximide suppresses the paroxysmal three cycle per second spike and wave activity associated with lapses of consciousness which is common in absence (petit mal) seizures. The frequency of epileptiform attacks is reduced, apparently by depression of the motor cortex and…
Pharmacologic Class:
Anti-epileptic Agent
Indications (1)
Career Relevance
ZARONTIN carries minimal linked job opportunities and represents a legacy product with contracted commercial activity; career growth is constrained to defensive sales, compliance, and portfolio management roles rather than innovation or expansion. Professionals seeking dynamic product development, market entry strategy, or clinical advancement should consider competing portfolio assets.
Worked on ZARONTIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.